Lexaria BioscienceLEXX
Market Cap: $51.1M
About: Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.
Employees: 3
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
233% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 3
73% more capital invested
Capital invested by funds: $3.31M [Q1] → $5.72M (+$2.41M) [Q2]
12% more funds holding
Funds holding: 25 [Q1] → 28 (+3) [Q2]
7.17% more ownership
Funds ownership: 7.2% [Q1] → 14.37% (+7.17%) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Yi Chen 43% 1-year accuracy 58 / 136 met price target | 210%upside $10 | Buy Reiterated | 18 Jul 2024 |
HC Wainwright & Co. Yi Chen 43% 1-year accuracy 58 / 136 met price target | 210%upside $10 | Buy Initiated | 10 Jul 2024 |
Financial journalist opinion
Based on 8 articles about LEXX published over the past 30 days